Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical marijuana, a move the Justice Department framed as the next step in carrying out President Donald Trump's December executive order on medical marijuana research. The order shifts qualifying marijuana from Schedule I, the most restrictive federal drug category, toward Schedule III under the Controlled Substances Act, placing it alongside substances like ketamine, anabolic steroids, and Tylenol with codeine.
The reclassification is narrow by design. Marijuana that falls outside an FDA-approved drug product or a state medical marijuana license stays right where it has been, Schedule I, and anyone handling it remains exposed to the full weight of federal regulatory controls and criminal sanctions.
That distinction matters. This is not blanket legalization. It is not even blanket rescheduling. It is a targeted federal accommodation for a medical-use framework that 38 states have already built on their own, while 24 states and Washington, D.C., have gone further and permitted recreational use. The federal government, in other words, is catching its rules up to a reality that has been expanding on the ground for years, but only for the medical lane, and only under state licensure.
The Justice Department announced updates to expedite the rulemaking process needed to move the drug from Schedule I to Schedule III. The order itself draws a hard line. As the document states:
"Any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance, and those who handle such material remain subject to the regulatory controls, and administrative, civil, and criminal sanctions."
That language leaves no ambiguity about recreational marijuana, black-market operations, or products sold outside licensed state programs. Federal enforcement authority over those categories is unchanged.
A separate statement from the Justice Department cast the move as research-driven. "This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information," the department said.
The reclassification builds directly on an executive order President Trump signed in December directing the federal government to increase medical marijuana research. A White House official told the Daily Mail that the administration's goal is straightforward:
"The Administration continues to expeditiously implement President Trump's December executive order to increase medical marijuana research to close the gap between current medical marijuana use and medical knowledge."
That gap is real. Tens of millions of Americans use marijuana under state medical programs, but the substance's Schedule I status has for decades made federally approved clinical research difficult to conduct. Researchers needed special DEA licenses, faced strict supply limitations, and operated under bureaucratic hurdles that did not apply to less restricted drugs. Moving medical marijuana to Schedule III eases those barriers without removing federal oversight.
The Biden administration had also moved toward rescheduling marijuana to Schedule III, but that rule was never finalized. What Trump's DOJ has done is pick up the policy goal, anchor it to a presidential executive order, and narrow the scope to state-licensed medical use, a more disciplined approach than the open-ended rescheduling discussion that stalled under the prior administration.
DEA Administrator Terry Cole made clear that the reclassification does not signal any softening on drug enforcement. In a related development, the Supreme Court has been weighing the intersection of drug law and firearms rights, a question that could take on new dimensions as marijuana's federal classification shifts.
Cole framed the administrative hearing process as a matter of restoring order to a policy area that has drifted without clear federal direction. He stated:
"Under the direction of President Trump and Acting Attorney General Blanche, DEA is expeditiously moving forward with the administrative hearing process, bringing consistency and oversight to an area that has lacked both."
He followed that with a pointed reminder about the agency's broader mission: "Our men and women in law enforcement remain committed to fighting drug cartels, the fentanyl epidemic, and protecting American lives."
That second sentence reads like a deliberate signal. The fentanyl crisis has claimed more American lives than any single drug epidemic in the nation's history, and the DEA wants no one to confuse a medical marijuana reclassification with a retreat from the drug war's most urgent front.
Not everyone on the right is cheering. Rep. Andy Harris of Maryland, the Freedom Caucus chairman and a physician by training, voiced sharp opposition. Harris said he does not approve of the order.
"We don't need rescheduling to do medical research on marijuana, all we are doing is exposing more of our youth to an addictive drug."
Harris's objection carries weight. He is not a backbencher looking for a headline; he chairs the House Freedom Caucus and brings a medical background to the argument. His concern, that rescheduling sends a cultural signal beyond its legal scope, reflects a real tension within the conservative coalition. Some see the move as federalism done right: Washington finally aligning its rules with state-level medical frameworks. Others, like Harris, see it as a concession that will be exploited to normalize broader marijuana use.
That debate is worth having honestly. Schedule III classification does not make marijuana available over the counter. It does not preempt state law. It does not legalize recreational use. But it does lower the federal government's official assessment of the drug's danger, and in politics, symbolism often travels faster than statute text.
It is worth noting that ketamine, one of the other Schedule III substances, has drawn its own political attention lately. Rep. Alexandria Ocasio-Cortez's campaign spent nearly $19,000 on a psychiatrist known for ketamine therapy and labeled it "leadership training," a reminder that Schedule III drugs already occupy a complicated space in American life and politics.
The DOJ's announcement describes an expedited rulemaking process, not a finished rule. Administrative hearings still lie ahead. The DEA must move through its own procedural steps. And Congress, where figures like Harris hold real influence, will have opportunities to weigh in, or push back, as the process unfolds.
The order also leaves several questions unanswered. How quickly will the rulemaking proceed? Will the final rule survive legal challenge? And will the narrow scope, state-licensed medical marijuana only, hold under political pressure from legalization advocates who will inevitably argue that the distinction between medical and recreational use is arbitrary?
For now, the Trump administration has staked out a position that threads a difficult needle: honoring the president's executive order, expanding research access, respecting state medical frameworks, and maintaining federal enforcement authority over everything else. Whether that balance holds will depend on whether the administration enforces the boundaries it just drew.
Washington has a long habit of opening doors marked "limited" and then forgetting to close them. The test of this order is not the signing, it is what happens when someone tries to walk through it sideways.
